UBS Maintains Neutral on Amrize, Lowers Price Target to $42

Benzinga Newsdesk www.benzinga.com Negative 67.7%

Neg 67.7% Neu 0% Pos 0%

UBS analyst Julian Radlinger maintains Amrize (NYSE:AMRZ) with a Neutral and lowers the price target from $57 to $42.

Comments

No comments yet. Be the first!